Is Statin Use Associated with Reduced Mortality After Pneumonia? A Systematic Review and Meta-analysis - 23/10/12
![](/templates/common/images/mail.png)
![](/templates/common/images/entites/204e.gif)
Abstract |
Objective |
The objective of this study was to perform a systematic review and meta-analysis of the effects of statins on mortality following pneumonia.
Methods |
We searched MEDLINE, EMBASE, BIOSIS, Cochrane CENTRAL Register of Controlled Trials, Cambridge Scientific Abstracts, BIOSIS, and Scopus. Studies were included if they involved: participants ≥18 years of age; patients with community-acquired pneumonia; current statin users; and reported overall or adjusted mortality after pneumonia.
Results |
Of 491 citations identified, 13 studies involving 254,950 patients met eligibility criteria. Pooled unadjusted data showed that statin use was associated with lower mortality after pneumonia (odds ratio [OR] 0.62, 95% confidence interval [CI], 0.54-0.71). Pooling of adjusted data also showed reduced mortality after pneumonia (OR 0.66, 95% CI, 0.55-0.79). However, this effect was attenuated in subgroup analysis by confounders and in prospective studies.
Conclusions |
Although statin use is associated with decreased mortality after pneumonia, this effect weakens in important subgroups. Only a randomized controlled study can fully explore the link between statins and pneumonia mortality.
Le texte complet de cet article est disponible en PDF.Keywords : Inflammation, Mortality, Outcomes, Pneumonia, Statins
Plan
Funding: None. |
|
Conflict of Interest: None. |
|
Authorship: All authors had access to the data, participated in the conception, design, writing, editing, and final approval of the manuscript. |
Vol 125 - N° 11
P. 1111-1123 - novembre 2012 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?